PL428992A1 - Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą - Google Patents

Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą

Info

Publication number
PL428992A1
PL428992A1 PL428992A PL42899219A PL428992A1 PL 428992 A1 PL428992 A1 PL 428992A1 PL 428992 A PL428992 A PL 428992A PL 42899219 A PL42899219 A PL 42899219A PL 428992 A1 PL428992 A1 PL 428992A1
Authority
PL
Poland
Prior art keywords
degree
determining
gal
patient
protein
Prior art date
Application number
PL428992A
Other languages
English (en)
Other versions
PL240124B1 (pl
Inventor
Ewa Łucja Stępień
Agnieszka Kamińska
Original Assignee
Uniwersytet Jagielloński
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński filed Critical Uniwersytet Jagielloński
Priority to PL428992A priority Critical patent/PL240124B1/pl
Priority to PCT/PL2020/050020 priority patent/WO2020171724A1/en
Publication of PL428992A1 publication Critical patent/PL428992A1/pl
Publication of PL240124B1 publication Critical patent/PL240124B1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6827—Total protein determination, e.g. albumin in urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób określanie stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą, charakteryzuje się tym, że w próbce moczu od pacjenta cierpiącego na cukrzycę określa się stężenie białka gal-3, przy czym: wartość stężenia białka gal-3 w moczu poniżej 11,06 ng/mL świadczy o istnieniu u tego pacjenta stopnia uszkodzenia nerek odpowiadającego umiarkowanie ciężkiemu lub ciężkiemu obniżeniu współczynnika przesączania kłębuszkowego eGFR poniżej 44 ml/min/1,73 cm2, wartość stężenia białka gal-3 w moczu powyżej 11,06 ng/mL świadczy o istnieniu u tego pacjenta stopnia uszkodzenia nerek odpowiadającego umiarkowanemu, niewielkiemu lub łagodnemu obniżeniu współczynnika przesączania kłębuszkowego eGFR do wartości powyżej 44 ml/min/1,73 cm2.
PL428992A 2019-02-21 2019-02-21 Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą PL240124B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL428992A PL240124B1 (pl) 2019-02-21 2019-02-21 Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą
PCT/PL2020/050020 WO2020171724A1 (en) 2019-02-21 2020-02-21 Method of determination of the degree of renal damage occurring in subjects with diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL428992A PL240124B1 (pl) 2019-02-21 2019-02-21 Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą

Publications (2)

Publication Number Publication Date
PL428992A1 true PL428992A1 (pl) 2020-08-24
PL240124B1 PL240124B1 (pl) 2022-02-21

Family

ID=70334017

Family Applications (1)

Application Number Title Priority Date Filing Date
PL428992A PL240124B1 (pl) 2019-02-21 2019-02-21 Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą

Country Status (2)

Country Link
PL (1) PL240124B1 (pl)
WO (1) WO2020171724A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150275301A1 (en) * 2012-10-05 2015-10-01 Hitachi Chemical Co., Ltd. URINE EXOSOME mRNAS AND METHODS OF USING SAME TO DETECT DIABETIC NEPHROPATHY

Also Published As

Publication number Publication date
PL240124B1 (pl) 2022-02-21
WO2020171724A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
WO2012040073A3 (en) Biomarkers of renal injury
EP3761034A3 (en) Urine biomarkers for prediction of recovery after acute kidney injury: proteomics
EP3773880A4 (en) Therapeutic modulation to treat blood glucose abnormalities, including type 2 diabetes, and/or reduce hba1c levels, and associated systems and methods
DE60329589D1 (de) Antikörper gegen den humanen "insulin-like" wachstumsfaktor
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
WO2007143098A3 (en) Hepatocyte growth factor (hgf) binding proteins
PL428992A1 (pl) Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą
WO2014099633A3 (en) Inhibitors of the renal outer medullary potassium channel
WO2011089234A3 (en) Aqueous solution comprising 3 - quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease
EA200700273A1 (ru) Способ лечения гиперфосфатемии c использованием гидроксикарбоната лантана
RU2016147122A (ru) Применение серелаксина для снижения gdf-15
BRPI0610704B8 (pt) composição do fator de crescimento epidérmico, o processo para isso e sua aplicação
MX2007003094A (es) 4-(metilo ciclico condensado)-imidazol-2-tionas como agonistas alfa2 adrenergicos.
EP3441768A3 (en) Marker for statin treatment stratification in heart failure
Niri et al. Renal function and plasma renin activity as potential factors causing hyperkalemia in patients with thyroid carcinoma undergoing thyroid hormone withdrawal for radioactive iodine therapy
Wyatt et al. Folic acid supplementation and chronic kidney disease progression
JOP20200046A1 (ar) طرق لعلاج أمراض مرتبطة بـtnf?
MX2024000251A (es) Efpeglenatida para reducir el riesgo de desarrollar enfermedad cardiovascular 0 disfunción renal.
MX2023014359A (es) Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico.
SCHOU Experimental Studies on Kidney Function during Sulphate Diuresis. 3. Investigations on the Tubular Function of Rabbit Kidneys during Infusion of a Hypertonic Sulphate‐solution. 1
Boudville et al. Factors associated with chronic kidney disease progression in Australian nephrology practices
Zheng et al. Urinary excretion of angiogenesis factors in chronic glomerulonephritis patients: Association with clinical activity and urinary biomarkers of kidney injury
Moorani et al. Vitamin D status in children with chronic kidney disease
Putra et al. MO577 EXPANDING THE POTENTIAL BENEFITS OF FERRIC CITRATE FOR IMPROVING IRON-DEFICIENCY ANAEMIA AND MINERAL BONE DISORDER PARAMETERS IN NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE PATIENTS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
堀越隆伸 Umbilical cord serum concentrations of perfluorooctane sulfonate, perfluorooctanoic acid, and the body mass index changes from birth to 5 1/2 years of age: A longitudinal study